Clinical trials: Primary Insomnia
Primary Insomnia
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia
- Trial name
- NCT00209950
- Testing
- Gaboxadol
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
The purpose of this study is determine whether this drug will improve your insomnia in terms of decreasing your time to fall asleep and allowing you to stay asleep longer.
- Trial name
- NCT00420810
- Testing
- MK0928 / Duration of Treatment : 8 Weeks
- Volunteers
- 138 people
- Sponsor
- H. Lundbeck A/S
Insomnia
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia
The primary objective of the study is to evaluate the safety and tolerability of Neu-P11, following the administration of multiple ascending oral doses (2, 5, 20, 50 mg or matching placebo) given nightly over 2 periods of 5 days…
- Trial name
- NCT01114126
- Testing
- Neu-P11
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Insomnia
Effects of Insomnia on Simulated Driving (MK-0000-183-00)
This is a double-blind, parallel design study in elderly primary insomnia patients and demographically matched controls. The objectives if this study are primarily: 1.
- Trial name
- NCT01209728
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
- Trial name
- RESTORA 1 (NCT00608985)
- Testing
- almorexant, zolpidem
- Where
- 91 sites in Australia, Austria and 18 more
- Volunteers
- 709 people
- Sponsor
- Midnight Pharma, LLC
Primary Insomnia
Comparison of Two Temperatures to Treat Insomnia
Insomnia patients demonstrate subjective and physiological hyperarousal. The Cereve Sleep System has been proposed as a clinical treatment to reverse this hyperarousal in insomnia patients.
- Trial name
- NCT01790256
- Testing
- Cereve Sleep System at 30 degrees C, Cereve Sleep System at 14-16 degrees C
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Cereve, Inc.
Insomnia
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
This study will establish the safety and tolerability of suvorexant (MK-4305) when administered for up to 14 months. Participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (DB) Treatment…
- Trial name
- NCT01021813
- Testing
- Suvorexant
- Volunteers
- 781 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
This is a randomised, placebo controlled study to evaluate the efficacy of a 3 week treatment period with Circadin® 2 mg in shortening sleep latency in patients with primary insomnia aged 18-80 with melatonin deficiency.
- Trial name
- NCT00397189
- Testing
- Circadin
- Where
- United Kingdom
- Volunteers
- 930 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- SAMS12 (NCT00495885)
- Testing
- volinanserin (M100907)
- Where
- 16 sites in United States, Brazil and 14 more
- Volunteers
- 848 people
- Sponsor
- Sanofi
Primary Insomnia
Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs
The aim of this placebo controlled study is to investigate the effect of 2 mg melatonin Slow Release (Circadin®) on the sleep/wake cycle in elderly insomniac out-subjects, aged 55 years or more.
- Trial name
- Neu I (NCT00816673)
- Testing
- Circadin
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Primary Insomnia
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
The purpose of this study is to further explore an effective dose range of PD0200390 for the treatment of patients with insomnia.
- Trial name
- NCT00551148
- Testing
- PD 0200390
- Where
- 16 sites in United States
- Volunteers
- 92 people
- Sponsor
- Pfizer
Insomnia
A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
Part A: The purpose of this study is to evaluate the safety and tolerability of single oral doses of E2006 administered in the morning to healthy male and female subjects.
- Trial name
- NCT01463098
- Testing
- E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg
- Where
- 2 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Insomnia
Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)
The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries…
- Trial name
- RUBY (NCT00482612)
- Testing
- Esmirtazapine
- Volunteers
- 526 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209924
- Testing
- Gaboxadol
- Where
- Sweden
- Volunteers
- 505 people
- Sponsor
- H. Lundbeck A/S
Sleep Initiation and Maintenance Disorders
Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties
The primary objective is to compare the potential for next-day residual effects of eplivanserin 5 mg/day and lormetazepam 1 mg/day by measuring the sleepiness in the morning using the patient's sleep questionnaire during 4 weeks…
- Trial name
- DREAMS (NCT00679900)
- Testing
- eplivanserin (SR46349), lormetazepam
- Where
- 8 sites in Chile, Estonia and 6 more
- Volunteers
- 283 people
- Sponsor
- Sanofi
Sleep Initiation and Maintenance Disorders, Insomnia
Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia
The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance of patients with primary insomnia using night polysomnography recordings over a 6-week treatment period corresponding to a stabilization…
- Trial name
- EPOCH (NCT00308503)
- Testing
- eplivanserin (SR46349)
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 608 people
- Sponsor
- Sanofi
Sleep Initiation and Maintenance Disorders
A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia
Patients with Primary Insomnia will be treated with GW597599 and GR205171 to evaluate the efficacy in the sleep difficulties associated with insomnia
- Trial name
- NCT00606697
- Testing
- GR205171, GW597599
- Where
- 10 sites in Germany
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Sleep Initiation and Maintenance Disorders, Primary Insomnia
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
The purpose of this study is to investigate the efficacy and safety of zolpidem MR (modified release) compared to zolpidem IR (immediate release) in patients with primary insomnia.
- Trial name
- NCT01181232
- Testing
- Zolpidem MR, Zolpidem IR
- Where
- 2 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Primary Insomnia
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.
- Trial name
- NCT00770510
- Testing
- Eszopiclone 1 mg, Eszopiclone 2 mg, Eszopiclone 3 mg
- Where
- 20 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Eisai Co., Ltd.
Sleep Initiation and Maintenance Disorders
Efficacy Study of EVT 201 to Treat Insomnia
The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating people diagnosed with primary insomnia ( difficulty sleeping with no other significant contributing factor, such as…
- Trial name
- NCT00380003
- Testing
- EVT 201
- Where
- 5 sites in United States
- Volunteers
- 66 people
- Sponsor
- Evotec Neurosciences GmbH